Business Context and Reporting Period
Company: Fluent, Inc. (FLNT)
Filing Type: Form 8-K (Current Report)
Date of Report: March 19, 2025
Event: Entry into a Material Definitive Agreement and Unregistered Sales of Equity Securities.
Key Financial Metrics
This filing reports a capital raise transaction rather than periodic operating results. Specific metrics include:
- Net Proceeds: Approximately $5.0 million (after deducting offering expenses).
- Securities Issued: 2,332,104 Unregistered Pre-Funded Warrants.
- Purchase Price: $2.174 per Unregistered Pre-Funded Warrant.
- Exercise Price: $0.0005 per share.
- Use of Proceeds: General corporate purposes, including capital expenditures, working capital, and general and administrative expenses.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a transaction-specific report.
Material Changes
The primary material change is the execution of securities purchase agreements with "Inside Investors" (officers/directors) and certain stockholders, including the Company's largest stockholder. This transaction resulted in the issuance of pre-funded warrants to purchase common stock. Additionally, the Company amended existing Support Agreements dated November 29, 2024, to include these new agreements and warrants.
Outlook, Risks, and Contingencies
- Stockholder Approval Requirement: The exercise of warrants issued to Inside Investors is contingent upon stockholder approval.
- Approval Timeline: The Company must use reasonable best efforts to obtain approval at the next annual meeting. If not obtained, an additional meeting must be held within 90 days, followed by semi-annual meetings until approval is secured.
- Transaction Closing: The sale of the Unregistered Warrants closed on March 20, 2025.
- Legal Disclaimer: Representations and warranties in the Purchase Agreements are for risk allocation between parties and do not constitute statements of fact for investors.
Investor Verification Checklist
- Verify the exact number of shares underlying the 2,332,104 pre-funded warrants and the potential dilution impact.
- Confirm the date of the next annual stockholder meeting to assess the timeline for required approval of Inside Investor warrant exercises.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Support Agreement Amendment (Exhibit 10.2) for specific covenants and conditions.
- Monitor subsequent filings for the outcome of the stockholder vote regarding the Inside Investor warrants.